The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Treatment breaks due to mucositis in patients with head and neck (H&N) cancer.

Print

Sub-category:
Head and Neck Cancer

Category:
Head and Neck Cancer

Meeting:
2008 ASCO Annual Meeting

Abstract No:
17024

Citation:
J Clin Oncol 26: 2008 (May 20 suppl; abstr 17024)

Author(s):
S. Patel, M. Abboud-Finch, J. A. Petersen, J. T. Marron, V. K. Mehta

Abstract:

Background: Mucositis is a primary factor limiting the dose intensity of radiation therapy (RT) in H&N cancer. Because reduced dose intensity can affect survival, we studied whether mucositis affected dose intensity in patients treated for H&N cancer. Methods: Patients with H&N cancer (or family members) who had registered to use NexCura's online NexProfiler Treatment Option Tool for H&N Cancer between Aug 2001 & Oct 2006 and previously opted to participate in surveys were invited to complete an online survey about their treatment experience. Of the 5246 individuals invited, 233 completed the survey of 84 questions during a 4 week period in Jan-Feb 2007. All eligible patients had received RT as part of their treatment. Results: 74% of respondents were male. 86% had completed treatment in 2001-2006. 15% received RT alone, 85% received RT + chemotherapy. 77% of all patients rated mucositis as the most severe treatment side effect. 30% of patients had an RT break to recover from a side effect. Of these, 38% said RT was stopped >2 times and 43% said RT was stopped for >5 days (4% for >10 days). The top 3 reasons for RT breaks were mouth pain, skin burn, and dehydration. 46% of patients cited some form of mucositis (difficulty/pain on swallowing; mouth soreness; mouth sores/ulcers; pain and/or burning; throat soreness; inability to swallow food/solids, liquids, or own saliva) as the primary or secondary reason for RT breaks. 33% of 199 patients had delays or early termination of chemotherapy due to side effects; the top 3 reasons were neutropenia, dehydration, and anemia. 13% reported mouth sores/ulcers, mouth pain, or swallowing difficulty as a primary or secondary reason for interruption of chemotherapy. Conclusions: In a large survey of patients who had undergone treatment for H&N cancer, the patients felt that mucositis was the most common reason for interruption of RT.


Abstract Disclosures

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.


  Associated Presentation(s):

    

No items found.


  Other Abstracts in this Sub-Category:

    

1. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM).

Meeting: 2008 ASCO Annual Meeting   Abstract No: 2010b   First Author: T. F. Cloughesy
Category: Head and Neck Cancer

    

2. Concomitant chemoradiotherapy (CT/RT) vs neoadjuvant chemotherapy with docetaxel/cispaltin/5-fluorouracil (TPF) followed by CT/RT in locally advanced head and neck cancer. Final results of a phase II randomized study.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 6000   First Author: A. Paccagnella
Category: Head and Neck Cancer

    

3. Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 6001   First Author: R. B. Tishler
Category: Head and Neck Cancer

    

More...


  Abstracts by S. Patel :

    

1. A phase II study of gefitinib in patients with metastatic melanoma.

Meeting: 2009 ASCO Annual Meeting   Abstract No: 9057   First Author: S. Patel
Category: Melanoma

    

2. A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

Meeting: 2009 ASCO Annual Meeting   Abstract No: 10563   First Author: A. P. Conley
Category: Sarcoma - Gastrointestinal Stromal Tumors

    

3. A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas.

Meeting: 2009 ASCO Annual Meeting   Abstract No: 10503   First Author: S. Patel
Category: Sarcoma - Other: Sarcoma

    

More...


  Presentations by S. Patel :

    

No items found.


  Educational Book Manuscripts by S. Patel :

    

No items found.




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.